AstraZeneca PLC ADR (AZN): Price and Financial Metrics

AstraZeneca PLC ADR (AZN): $66.08

-0.13 (-0.20%)

POWR Rating

Component Grades














  • Sentiment is the dimension where AZN ranks best; there it ranks ahead of 96.1% of US stocks.
  • The strongest trend for AZN is in Value, which has been heading up over the past 178 days.
  • AZN's current lowest rank is in the Momentum metric (where it is better than 12.39% of US stocks).

AZN Stock Summary

  • With a market capitalization of $204,707,520,000, ASTRAZENECA PLC has a greater market value than 99.28% of US stocks.
  • AZN's current price/earnings ratio is 100.4, which is higher than 95.35% of US stocks with positive earnings.
  • In terms of volatility of its share price, AZN is more volatile than merely 12.89% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to ASTRAZENECA PLC, a group of peers worth examining would be NVS, BABA, BMY, DHR, and ABT.
  • AZN's SEC filings can be seen here. And to visit ASTRAZENECA PLC's official web site, go to

AZN Valuation Summary

  • In comparison to the median Healthcare stock, AZN's price/sales ratio is 4.26% lower, now standing at 4.5.
  • Over the past 242 months, AZN's EV/EBIT ratio has gone up 80.3.

Below are key valuation metrics over time for AZN.

Stock Date P/S P/B P/E EV/EBIT
AZN 2022-11-22 4.5 5.8 100.2 95.4
AZN 2022-11-21 4.5 5.8 99.3 94.6
AZN 2022-11-18 4.5 5.7 98.8 94.2
AZN 2022-11-17 4.4 5.6 97.3 92.9
AZN 2022-11-16 4.4 5.6 96.9 92.5
AZN 2022-11-15 4.4 5.6 97.1 92.7

AZN Growth Metrics

    Its 3 year revenue growth rate is now at 85.19%.
  • Its year over year cash and equivalents growth rate is now at -24.54%.
  • Its year over year net income to common stockholders growth rate is now at -126.73%.
Over the past 55 months, AZN's revenue has gone up $22,916,000,000.

The table below shows AZN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 45,154 8,828 2,039
2022-06-30 44,038 7,617 -1,253
2022-03-31 41,487 7,261 -1,063
2021-12-31 37,417 5,963 112
2021-12-31 37,417 5,963 112
2021-09-30 32,816 6,343 1,471

AZN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AZN has a Quality Grade of B, ranking ahead of 78.56% of graded US stocks.
  • AZN's asset turnover comes in at 0.438 -- ranking 104th of 681 Pharmaceutical Products stocks.
  • CLVS, HSKA, and FLXN are the stocks whose asset turnover ratios are most correlated with AZN.

The table below shows AZN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.438 0.765 0.209
2021-03-31 0.431 0.792 0.231
2020-12-31 0.429 0.801 0.205
2020-09-30 0.427 0.801 0.174
2020-06-30 0.433 0.800 0.161
2020-03-31 0.422 0.794 0.126

AZN Stock Price Chart Interactive Chart >

Price chart for AZN

AZN Price/Volume Stats

Current price $66.08 52-week high $71.70
Prev. close $66.21 52-week low $52.65
Day low $65.88 Volume 3,345,962
Day high $66.46 Avg. volume 6,829,364
50-day MA $58.78 Dividend yield 1.37%
200-day MA $63.03 Market Cap 204.77B

AstraZeneca PLC ADR (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Latest News Stream

Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.

AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M

The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.

Yahoo | November 28, 2022

AstraZeneca Bets On UK Listed Firm For Lung Diseases

Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) worth up to $402 million for its NRF2 Activator program. C4X Discovery is listed on the London Stock exchange, and the deal is the third significant deal with a major pharmaceutical company. AstraZeneca will develop and commercialize an oral therapy for inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). Re

Yahoo | November 28, 2022

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with

Yahoo | November 28, 2022

11 Best Diabetes Stocks To Buy Now

In this article, we discuss 11 best diabetes stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Diabetes Stocks To Buy Now. The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition. Based on the type, the […]

Yahoo | November 27, 2022

10 Best Biotech Stocks To Buy According To Hedge Funds

In this article, we discuss 10 best biotech stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy According To Hedge Funds. In 2023, digitalization will increase in the biotech industry as the possibility of online and remote assessment, diagnosis, […]

Yahoo | November 25, 2022

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 12.55%
3-mo 5.93%
6-mo -0.65%
1-year 21.76%
3-year 47.22%
5-year 133.08%
YTD 16.08%
2021 19.66%
2020 3.06%
2019 35.58%
2018 13.77%
2017 33.10%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6999 seconds.